LEVULAN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LEVULAN (LEVULAN).
Levulan (aminolevulinic acid) is a photosensitizing agent. It is converted intracellularly into protoporphyrin IX, which accumulates in cells. Upon exposure to light of appropriate wavelength, protoporphyrin IX generates reactive oxygen species, leading to cellular damage and apoptosis.
| Metabolism | Aminolevulinic acid is metabolized via the heme biosynthesis pathway; it is converted to protoporphyrin IX in cells, then to heme. Metabolism occurs primarily in the liver and erythrocytes. |
| Excretion | Primarily fecally (biliary) as protoporphyrin IX; renal excretion is negligible (<4% of absorbed dose). |
| Half-life | Topical: aminolevulinic acid (ALA) has a terminal half-life of approximately 1–2 hours in plasma; protoporphyrin IX (PpIX) accumulates locally and persists for 24–48 hours. |
| Protein binding | Aminolevulinic acid: <5% bound; protoporphyrin IX: highly bound to hemoglobin and albumin. |
| Volume of Distribution | Aminolevulinic acid: 0.5–0.7 L/kg; protoporphyrin IX distribution is primarily intracellular (mitochondria) and not quantified as Vd. |
| Bioavailability | Topical: <1% systemic absorption (bioavailability not relevant orally). |
| Onset of Action | Topical: Photodynamic effect begins within 14–18 hours after application of ALA and 30–60 minutes of blue light exposure. |
| Duration of Action | Local photosensitivity lasts 24–48 hours; patients should avoid sunlight for at least 40 hours after application. |
20% topical solution applied to lesion and surrounding 5 mm of normal skin; then illuminated with blue light (417 nm) for 1000 seconds (16 minutes 40 seconds) 14 to 18 hours after application.
| Dosage form | SOLUTION |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dosage adjustment recommended for geriatric patients; use standard adult dosing. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LEVULAN (LEVULAN).
| Breastfeeding | No data on the presence of Levulan in human milk, effects on breastfed infant, or milk production. Systemic absorption after topical application is minimal, making significant transfer via breast milk unlikely. However, due to lack of data and potential genotoxicity, caution is advised. Avoid breastfeeding for the first 5-7 days after treatment to minimize any theoretical risk. M/P ratio not available. |
| Teratogenic Risk | FDA Pregnancy Category C. Animal studies have shown fetal harm (elevated rates of embryonic death, structural abnormalities) at doses several-fold the human clinical dose based on mg/kg. No adequate and well-controlled studies in pregnant women. Levulan (aminolevulinic acid hydrochloride) topical solution, used in photodynamic therapy, is applied topically and systemic absorption is minimal (<1%) after application. However, because of potential genotoxicity (active metabolite can cause DNA damage), avoid use during pregnancy unless clearly necessary. Risk cannot be ruled out for any trimester; use only if potential benefit justifies potential risk to fetus. |
■ FDA Black Box Warning
No black box warning.
| Serious Effects |
["Hypersensitivity to aminolevulinic acid or any components","Porphyria","Concurrent use of photosensitizing drugs","Known sensitivity to light (e.g., photosensitivity disorders)"]
| Precautions | ["Photosensitivity: avoid exposure to sunlight or bright indoor light for at least 40 hours after application","Local skin reactions: severe erythema, edema, and crusting may occur","Ophthalmic: avoid eye contact; can cause corneal damage","Carcinogenicity: possible increased risk of skin cancer with repeated use"] |
Loading safety data…
| Fetal Monitoring | No specific maternal or fetal monitoring requirements beyond standard prenatal care. Ensure photosensitizing agents are not administered to pregnant women unless necessary. Monitor for local skin reactions in the mother (erythema, edema, burning) at application site, but no fetal monitoring specifically indicated. |
| Fertility Effects | No human data. Animal studies: no impairment of fertility in rats at doses up to 200 mg/kg/day (subcutaneous); however, no reproductive toxicity studies with topical application. Based on mechanism (photosensitizer), no anticipated direct effects on fertility, but lack of comprehensive data precludes definitive conclusions. |